Find your tools for building human cell-based models & screening assays
Axol uses human iPSCs to generate specific cell types We do NOT use animal cells or embryonic stem cells (ESCs)
Featured Product
Microglia
Human iPSC-derived Microglia provide a reliable and consistent model that phenotypically recapitulates human microglia responses in vitro.
Featured Service
Cell Reprogramming
A complete suite of custom cell reprogramming and characterization services from dedicated specialists to generate iPSCs from human cells using cutting edge technologies.
Featured White Paper
Atrial Cardiomyocytes
Are you using non-human cell models for your cardiac research? Download our new white paper to find out why human iPSC-derived Atrial Cardiomyocytes could improve your data.
Welcome to Axol Bioscience
YOUR HUMAN CELL CULTURE SPECIALISTS
We provide highly validated human iPSC-derived cells and primary cells from healthy donors and patients of specific disease backgrounds, together with optimized media and growth supplements. Axol aims to develop the best human cell biology research tools to advance medical research and drug discovery. Combining our passion for science with quality, innovation and customer service, we deliver robust and reliable products that our customers need to advance their research faster.
Axol Bioscience launch human iPSC-derived Microglia
13 December 2018
Cambridge, UK – (6th December 2018) – Axol Bioscience, the human cell culture specialist, is launching a new line of Human induced Pluripotent Stem Cells (iPSC)-derived Microglia for the consistent and reproducible study of neuroglia and their involvement in neurodegenerative diseases, including Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.
Good Cell Culture Practice in Toxicology Seminar
16 October 2018
Axol Bioscience is presenting at the two-day seminar hold by Evercyte and Altetox in Vienna, from 30-31 October. Book your ticket today.
Three reasons why iPSC-derived atrial cardiomyocytes are poised to accelerate atrial fibrillation research
1 October 2018
Atrial fibrillation is estimated to affect around 6 million people in Europe, making it the most common arrhythmia observed in the clinic. The irregular heartbeat and disturbed electrical activity experienced by atrial fibrillation patients is commonly treated by surgical interventions such as pacemakers or the ablation of diseased tissue, or with non-selective class IC (Nav) and III (Kv) ion channel anti-arrhythmic drugs. However, these approaches can have serious side-effects, so extensive research has been devoted to better understand the cellular mechanisms behind the disease to develop safer and more effective treatments.
iPSC-derived atrial cardiomyocytes: a reproducible platform for translational disease insights
10 September 2018
Atrial fibrillation is the most common arrhythmia observed in the clinic, affecting 6 million patients in Europe and accounting for 30% of strokes. The prevalence of atrial fibrillation continues to grow due to an aging population and is expected to double over the next 50 years. Given the need to develop safer and more effective anti-arrhythmic therapeutics, considerable efforts have been made to understand the cellular mechanisms of the disease and translate this knowledge into innovative treatments.
How to Order
To place an order or request a quotation simply add the desired products to your shopping cart and then click "Process Checkout" to provide the billing and shipping information. On the payment page you can then either pay immediately or download a quotation.
Order Confirmed
Thank you for your order. We have received your purchase order successfully and will start processing it as soon as possible.
We will be in touch shortly.
Issue with Order Detected
There was an issue with your submitted order as follows: Unidentified Error Please resolve this issue and try again. If you are unable to do so, please contact us via the contact form and we'll do our best to resolve your issue.
